Ionis Pharmaceuticals
IONS
367 hedge funds and large institutions have $5.62B invested in Ionis Pharmaceuticals in 2020 Q3 according to their latest regulatory filings, with 46 funds opening new positions, 110 increasing their positions, 129 reducing their positions, and 52 closing their positions.
1.42% less ownership
Funds ownership: 86.28% → 84.86% (-1.4%)
2% less funds holding
Funds holding: 375 → 367 (-8)
11% less call options, than puts
Call options by funds: $32.5M | Put options by funds: $36.6M
12% less first-time investments, than exits
New positions opened: 46 | Existing positions closed: 52
15% less repeat investments, than reductions
Existing positions increased: 110 | Existing positions reduced: 129
21% less capital invested
Capital invested by funds: $7.09B → $5.62B (-$1.47B)
29% less funds holding in top 10
Funds holding in top 10: 7 → 5 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$118M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$39.3M |
| 3 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$25.9M |
| 4 |
Two Sigma Investments
New York
|
+$19M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$12.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$183M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$48M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
-$38.2M |
| 4 |
ClearBridge Investments
New York
|
-$21.6M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$17.6M |
IONS Hedge Fund Activity: Q3 2020 in Review
367 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Ionis Pharmaceuticals (IONS) for Q3 2020, worth a combined $5.62B — down 21% from $7.09B a quarter earlier.
Sellers outnumbered buyers: 52 funds closed out of IONS and 46 opened new positions — a net loss of 6 holders — while 129 trimmed existing stakes and 110 added.
The largest buyer was T. Rowe Price Associates, adding an estimated $118M. The largest seller was Baillie Gifford & Co, cutting an estimated $183M.
- 367 institutional investors held Ionis Pharmaceuticals (IONS) as of Q3 2020, down from 375 in Q2 2020.
- Funds reported $5.62B of Ionis Pharmaceuticals stock for Q3 2020, down 21% quarter-over-quarter.
- 46 funds opened new Ionis Pharmaceuticals positions in Q3 2020 and 52 closed out, a net change of -6 holders.
- The largest Ionis Pharmaceuticals buyer in Q3 2020 was T. Rowe Price Associates, an estimated $118M added.
- The largest Ionis Pharmaceuticals seller in Q3 2020 was Baillie Gifford & Co, an estimated $183M sold.
Based on aggregated 13F filings for Q3 2020.